Fluticasone furoate: Glucocorticoid receptor agonist intranasal corticosteroid

Drugs of the Future

Volumn 32, Issue 1, 2007, Pages 12-16

  Sorbera, L A ^a   Serradell, N ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AVAMYS; BUDESONIDE; CORTICOSTEROID; FLUTICASONE FUROATE; GLUCOCORTICOID RECEPTOR; GW 685698X; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NS 126; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LOW DRUG DOSE; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34247577624     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.01.1065739     Document Type: Article

References (31)

1. Phillipps, G.H., Bain, B.M., Williamson, C., Steeples, I.P., Laing, S.B. (Glaxo Group, Ltd.). Androstane 17β-carbothioates. GB 2088877.
2. Biggadike, K., Jones, P., Payne, J.J. (Glaxo Group, Ltd.). 17beta-Carbothioate 17alpha-arylcarbonyloxyoxy androstane derivative as anti-inflammatory agents. EP 1305330, JP 2004505990, US 6537983, US 2003045512, WO 0212266.
3. Biggadike, K., Coote, S.J., Noga, B., Van Oort, M.M. (Glaxo Group, Ltd.). Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form. EP 1480996, JP 2005522442, US 2005152845, WO 03066655.
4. Partridge, J.J., Walker, D.S. (SmithKline Beecham Corp.). A method for preparing fluticasone derivatives. WO 03013427.
5. Prous Science Disease Briefings: Allergic Rhinitis (online publication). Updated 2007.
6. Quillen, D.M., Feller, D.B. Diagnosing rhinitis: Allergic vs. non-allergic. Am Fam Physician 2006, 73(9): 1583-90.
7. Holgate, S.T. The epidemic of allergy and asthma. Nature 1999, 402(6760): 2-4.
8. Bachert, C. et al. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 2002, 57(9): 841-55.
9. Plaut, M., Valentine, M.D. Allergic rhinitis. New Engl J Med 2005, 353(18): 1934-44.
10. Kaszuba, S.M. et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001, 161(21): 2581-7.
11. Biggadike, K., Bledsoe, R., Hassell, A., Hughes, S., Shewchuk, L. GW685698X - Enhanced affinity for the glucocorticoid receptor: Receptor crystal structure and route of metabolic inactivation. 25th Congr Eur Acad Allergol Clin Immunol (June 10-14, Vienna) 2006, Abst 783.
12. Valotis, A., Högger, P. Human receptor kinetics and tissue affinity of the enhanced affinity glucocorticoid GW685698X. 25th Congr Eur Acad Allergol Clin Immunol (June 10-14, Vienna) 2006, Abst 780.
13. Salter, M., Biggadike, K., Clackers, M., Solanke, Y., Matthews, J., Maschera, B., Haase, M. GW685698X - Enhanced affinity for the glucocorticoid receptor: Cellular and in vivo pharmacology. 25th Congr Eur Acad Allergol Clin Immunol (June 10-14, Vienna) 2006, Abst 781.
14. Stuebner, P. Effects of the novel intranasal glucocorticosteroid GW685698 (200 mcg once-daily) on seasonal allergic rhinitis (SAR) symptoms induced in the Vienna challenge chamber model (VCC). J Allergy Clin Immunol 2006, 117(2, Suppl. 1): Abst 1232.
15. Ziegimayer, P., Ziegimayer, R., Lemell, P., Bareille, P.J., Rousell, V., Salmon, E., Horak, F. A novel enhanced affinity glucocorticoid GW685698X 200 mcg once-daily improved seasonal allergic rhinitis (SAR) symptoms induced in the Vienna challenge chamber (VCC). 25th Congr Eur Acad Allergol Clin Immunol (June 10-14, Vienna) 2006, Abst 784.
16. Philpot, E., Faris, M., Toler, T., Wu, W. Once-daily GW685698X nasal spray effectively treats ocular symptoms of seasonal allegic rhinitis (SAR). 25th Congr Eur Acad Allergol Clin Immunol (June 10-14, Vienna) 2006, Abst 779.
17. Martin, B., Philpot, E., Faris, M., Toler, T., Wu, W. A dose-ranging study to evaluate the efficacy and safety of once daily GW685698X nasal spray in subjects with seasonal allergic rhinitis (SAR). 25th Congr Eur Acad Allergol Clin Immunol (June 10-14, Vienna) 2006, Abst 782.
18. Long term safety of GW685698X via nasal biopsy (NCT00224523). ClinicalTrials.gov Web site, January 1, 2007.
19. A study of GW685698X for the treatment of perennial allergic rhinitis in pediatrics (NCT00116883). ClinicalTrials.gov Web site, January 1, 2007.
20. A study of GW685698X for the treatment of perennial allergic rhinitis in adolescents and adults (NCT00116818). ClinicalTrials.gov Web site, January 1, 2007.
21. Once-daily investigational nasal spray in adults and adolescents with perennial allergic rhinitis (PAR) (NCT00289198). ClinicalTrials.gov Web site, January 1, 2007.
22. A study to evaluate the efficacy and safety of a once-daily investigational nasal spray in adults and adolescents with perennial allergic rhinitis (PAR) (NCT00103454). ClinicalTrials.gov Web site, January 1, 2007.
23. Perennial allergic rhinitis study in pediatric subjects (NCT00108914). ClinicalTrials.gov Web site, January 1, 2007.
24. Safety study to assess growth in children with seasonal allergic and/or perennial allergic rhiniis treated with GW685698X aqueous nasal spray or placebo nasal spray (NCT00109486). ClinicalTrials.gov Web site, January 1, 2007.
25. Study in adolescent and adult subjects 12 years of age and older with seasonal allergic rhinitis to assess onset of action (NCT00118729). ClinicalTrials.gov Web site, January 1, 2007.
26. Once-daily investigational nasal spray in adults and adolescents with seasonal allergic rhinitis (SAR) (NCT00197262). ClinicalTrials.gov Web site, January 1, 2007.
27. Study in adults and adolescents with seasonal allergic rhinitis (NCT00115622). ClinicalTrials.gov Web site, January 1, 2007.
28. Study in adults and adolescents with seasonal allergic rhini tis (NCT00225823). ClinicalTrials.gov Web site, January 1, 2007.
29. Study of adults and adolescents with vasomotor rhinitis (NCT00117325). ClinicalTrials.gov Web site, January 1, 2007.
30. Once-daily investigational nasal spray in adults and adolescents with vasomotor rhinitis (NCT00118703). ClinicalTrials.gov Web site, January 1, 2007.
31. To evaluate the efficacy and safety of GW685698X drug in adolescent and adult subjects with persistent asthma (NCT00398645). ClinicalTrials.gov Web site, January 1, 2007.